Clinical trials
Full profile accessFollow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Company intelligence / Profile preview
Neurotron Biotechnology
Hangzhou, Zhejiang, China
- Ownership
- Private
- Development stage
- Other
01
Overview
Nurotron Biotechnology commercially markets the Venus Cochlear Implant System for severe-to-profound hearing loss, with over 20,000 users worldwide. Additional neurostimulation systems for auditory brainstem implants, artificial retina, and stroke paralysis treatment are in development or patented.[1][5][9]
- Therapeutic areas
- OphthalmologyNeurology
- Modalities
- Cochlear implantNeurostimulation system
- Industry
- Implantable Medical Devices
02
Partnerships
China Disabled Persons’ Federation
Beyond the preview
Go deeper on Neurotron Biotechnology.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Licensing & deals
Full profile accessExplore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Full profile accessTrace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Full profile accessCompare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Full profile accessExplore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Full profile accessConnect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Neurotron Biotechnology.